^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + APG-1387 (IAP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 6216: Therapeutic potential of IAP inhibitor APG-1387 in combination with PARP- or MEK-targeted therapy, or chemotherapy in pancreatic cancer
Published date:
05/15/2020
Excerpt:
The results revealed that APG-1387 improved the antitumor activity of olaparib in 4 out of 6 (67%) BRCA1/2 mutant PDXs with a 44% reduction of T/C (%) value (T, treatment group, C, vehicle control), including one partial tumor regression (PR)….In summary, our results suggest that APG-1387 is a potential agent for pancreatic cancer treatment, ascribing to its potential synergistic antitumor effect by combining with either PARP inhibitors in BRCA1/2 mutant or MEK inhibitors in KRAS mutant pancreatic cancers.
DOI:
10.1158/1538-7445.AM2020-6216
